ERBB2 and breast cancer: Metastatic BC patients with HER2-positive hormone receptor-positive tumors are treated with dual HER2-targeted therapy (pertuzumab/trastuzumab) either in combination with chemotherapy or endocrine therapy within the DETECT V/CHEVENDO trial.